NYU Langone Health
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.
Inclusion Criteria: 1. One of the following: 1. A history of psoriasis as confirmed by a board-certified dermatologist OR 2. A history of psoriatic arthritis as confirmed by a board-certified rheumatologist 2. Age ≥ 18 \& \< 90 years 3. Able and willing to provide written informed consent for the study 4. English-speaking unless a translated informed consent form is approved 5. No previous antiplatelet or anticoagulant use for 14 days prior to enrollment Exclusion Criteria: 1. A prior history of a myocardial infarction, stroke/TIA, or occlusive peripheral arterial disease 2. Chronic…
81 mg capsule orally once daily for 4 weeks
75 mg capsule orally once daily for 4 weeks
Matching placebo (microcellulose powder) capsule orally once daily for 4 weeks
Arctuva estimate
Verify or correct the compensation shown for this listing.